

# Andrea Sboner

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/916599/andrea-sboner-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137  
papers

29,601  
citations

56  
h-index

155  
g-index

155  
ext. papers

36,678  
ext. citations

14.4  
avg, IF

8.2  
L-index

#	Paper	IF	Citations
137	An integrated encyclopedia of DNA elements in the human genome. <i>Nature</i> , <b>2012</b> , 489, 57-74	50.4	11449
136	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
135	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , <b>2015</b> , 163, 1011-25	56.2	1713
134	A user's guide to the encyclopedia of DNA elements (ENCODE). <i>PLoS Biology</i> , <b>2011</b> , 9, e1001046	9.7	1060
133	The genomic complexity of primary human prostate cancer. <i>Nature</i> , <b>2011</b> , 470, 214-20	50.4	984
132	Punctuated evolution of prostate cancer genomes. <i>Cell</i> , <b>2013</b> , 153, 666-77	56.2	862
131	Organoid cultures derived from patients with advanced prostate cancer. <i>Cell</i> , <b>2014</b> , 159, 176-187	56.2	847
130	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , <b>2016</b> , 22, 298-305	50.5	775
129	Integrative analysis of the <i>Caenorhabditis elegans</i> genome by the modENCODE project. <i>Science</i> , <b>2010</b> , 330, 1775-87	33.3	744
128	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , <b>2011</b> , 1, 487-95	24.4	550
127	Personalized and Cancer Models to Guide Precision Medicine. <i>Cancer Discovery</i> , <b>2017</b> , 7, 462-477	24.4	477
126	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , <b>2014</b> , 5, 5383	17.4	432
125	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11428-11436	11.5	383
124	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 645-651	36.3	380
123	Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 775-84	5	349
122	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , <b>2014</b> , 46, 1227-32	36.3	348
121	Integrative annotation of variants from 1092 humans: application to cancer genomics. <i>Science</i> , <b>2013</b> , 342, 1235587	33.3	281

120	Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. <i>Nature</i> , <b>2018</b> , 560, 499-503	50.4	277
119	Integrative functional genomic analysis of human brain development and neuropsychiatric risks. <i>Science</i> , <b>2018</b> , 362,	33.3	277
118	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , <b>2016</b> , 30, 563-577	24.3	256
117	Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 98ra82	17.5	252
116	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 815-25	9.7	251
115	The real cost of sequencing: higher than you think!. <i>Genome Biology</i> , <b>2011</b> , 12, 125	18.3	247
114	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. <i>JAMA Oncology</i> , <b>2015</b> , 1, 466-74	13.4	207
113	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. <i>BMC Medical Genomics</i> , <b>2010</b> , 3, 8	3.7	169
112	The role of disorder in interaction networks: a structural analysis. <i>Molecular Systems Biology</i> , <b>2008</b> , 4, 179	12.2	167
111	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , <b>2016</b> , 48, 1490-1499	36.3	161
110	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. <i>Genome Research</i> , <b>2011</b> , 21, 56-67	9.7	156
109	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , <b>2018</b> , 9, 2404	17.4	149
108	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , <b>2015</b> , 526, 453-7	50.4	144
107	Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 538-50	5	143
106	FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. <i>Genome Biology</i> , <b>2010</b> , 11, R104	18.3	121
105	Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. <i>Genes Chromosomes and Cancer</i> , <b>2014</b> , 53, 183-93	5	117
104	SPOP Mutation Drives Prostate Tumorigenesis InVivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. <i>Cancer Cell</i> , <b>2017</b> , 31, 436-451	24.3	116
103	SPOP mutations in prostate cancer across demographically diverse patient cohorts. <i>Neoplasia</i> , <b>2014</b> , 16, 14-20	6.4	113

102	SPOP mutation leads to genomic instability in prostate cancer. <i>ELife</i> , <b>2015</b> , 4,	8.9	110
101	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 43-51	12.9	110
100	Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 1075-87	5	99
99	N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. <i>Neoplasia</i> , <b>2009</b> , 11, 804-11	6.4	92
98	RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries. <i>Bioinformatics</i> , <b>2011</b> , 27, 281-3	7.2	89
97	Comparison and calibration of transcriptome data from RNA-Seq and tiling arrays. <i>BMC Genomics</i> , <b>2010</b> , 11, 383	4.5	88
96	FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. <i>Nature</i> , <b>2019</b> , 571, 408-412	50.4	81
95	Clinical features of neuroendocrine prostate cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 121, 7-18	7.5	79
94	TBIO-15. UTILIZING A HISTOLOGY-SPECIFIC SEQUENCING ALGORITHM FOR PRECISION NEURO-ONCOLOGY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i183-i183	1	78
93	A multiple classifier system for early melanoma diagnosis. <i>Artificial Intelligence in Medicine</i> , <b>2003</b> , 27, 29-44	7.4	75
92	Distinct genomic aberrations associated with ERG rearranged prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2009</b> , 48, 366-80	5	72
91	The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2017</b> , 24, 513-519	8.6	66
90	Genomic analysis of the hydrocarbon-producing, cellulolytic, endophytic fungus <i>Ascocoryne sarcoides</i> . <i>PLoS Genetics</i> , <b>2012</b> , 8, e1002558	6	64
89	Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 10296-303	10.1	64
88	Unraveling the clonal hierarchy of somatic genomic aberrations. <i>Genome Biology</i> , <b>2014</b> , 15, 439	18.3	61
87	Ubch10 expression may be a useful tool in the prognosis of ovarian carcinomas. <i>Oncogene</i> , <b>2007</b> , 26, 2136-40	9.2	61
86	Epigenomic alterations in localized and advanced prostate cancer. <i>Neoplasia</i> , <b>2013</b> , 15, 373-83	6.4	59
85	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	56

84	Genomics and privacy: implications of the new reality of closed data for the field. <i>PLoS Computational Biology</i> , <b>2011</b> , 7, e1002278	5	56
83	UbcH10 is overexpressed in malignant breast carcinomas. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2729-357.5		56
82	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 1653-1668	15.9	56
81	VAT: a computational framework to functionally annotate variants in personal genomes within a cloud-computing environment. <i>Bioinformatics</i> , <b>2012</b> , 28, 2267-9	7.2	55
80	Robust-linear-model normalization to reduce technical variability in functional protein microarrays. <i>Journal of Proteome Research</i> , <b>2009</b> , 8, 5451-64	5.6	55
79	N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 3924-3940	15.9	55
78	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. <i>Npj Genomic Medicine</i> , <b>2016</b> , 1,	6.2	51
77	Diverse protein kinase interactions identified by protein microarrays reveal novel connections between cellular processes. <i>Genes and Development</i> , <b>2011</b> , 25, 767-78	12.6	51
76	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6802-6811	12.9	50
75	Comparing classical pathways and modern networks: towards the development of an edge ontology. <i>Trends in Biochemical Sciences</i> , <b>2007</b> , 32, 320-31	10.3	49
74	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. <i>Cell</i> , <b>2020</b> , 183, 197-210.e32	56.2	45
73	MTSS1 is a metastasis driver in a subset of human melanomas. <i>Nature Communications</i> , <b>2014</b> , 5, 3465	17.4	43
72	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. <i>Cancer Cell</i> , <b>2017</b> , 32, 792-806.e7	24.3	39
71	ASEQ: fast allele-specific studies from next-generation sequencing data. <i>BMC Medical Genomics</i> , <b>2015</b> , 8, 9	3.7	38
70	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 471-80	13.4	38
69	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , <b>2018</b> , 72, 341-354.e6	17.6	38
68	Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 569-76	7.5	32
67	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , <b>2020</b> , 11, 5549	17.4	31

66	A primer on precision medicine informatics. <i>Briefings in Bioinformatics</i> , <b>2016</b> , 17, 145-53	13.4	30
65	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. <i>Cancer Cell</i> , <b>2019</b> , 35, 603-617.e8	24.3	29
64	Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. <i>Neoplasia</i> , <b>2013</b> , 15, 1231-40	6.4	28
63	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. <i>Cancer</i> , <b>2018</b> , 124, 1008-1015	6.4	24
62	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 1157-1164	6.1	23
61	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	23
60	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 381-386	15.9	23
59	PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6839-6851	12.9	22
58	Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. <i>Journal of Pathology</i> , <b>2018</b> , 246, 244-253	9.4	21
57	MAGI3-AKT3 fusion in breast cancer amended. <i>Nature</i> , <b>2015</b> , 520, E11-2	50.4	20
56	Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. <i>Genome Biology</i> , <b>2017</b> , 18, 141	18.3	20
55	Patient-derived xenografts and organoids model therapy response in prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 1117	17.4	18
54	CD38 is methylated in prostate cancer and regulates extracellular NAD. <i>Cancer &amp; Metabolism</i> , <b>2018</b> , 6, 13	5.4	18
53	TMABoost: an integrated system for comprehensive management of tissue microarray data. <i>IEEE Transactions on Information Technology in Biomedicine</i> , <b>2006</b> , 10, 19-27		17
52	Analysis of user-satisfaction with the use of a teleconsultation system in oncology. <i>Informatics for Health and Social Care</i> , <b>2003</b> , 28, 73-84		17
51	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	17
50	Building an international consortium for tracking coronavirus health status. <i>Nature Medicine</i> , <b>2020</b> , 26, 1161-1165	50.5	16
49	Inherited determinants of early recurrent somatic mutations in prostate cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 48	17.4	16

48	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	15
47	Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays. <i>Nucleic Acids Research</i> , <b>2010</b> , 38, 3275-86	20.1	15
46	Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond Mutations: A Comprehensive Genomic Analysis. <i>Cells</i> , <b>2020</b> , 9,	7.9	14
45	Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. <i>Nature Communications</i> , <b>2020</b> , 11, 1987	17.4	14
44	Automatic model selection in cost-sensitive boosting. <i>Information Fusion</i> , <b>2003</b> , 4, 3-10	16.7	14
43	Clinical validation of an automated system for supporting the early diagnosis of melanoma. <i>Skin Research and Technology</i> , <b>2004</b> , 10, 184-92	1.9	13
42	An automated procedure to properly handle digital images in large scale tissue microarray experiments. <i>Computer Methods and Programs in Biomedicine</i> , <b>2005</b> , 79, 197-208	6.9	13
41	The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. <i>Oncotarget</i> , <b>2016</b> , 7, 45597-45607	3.3	13
40	Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	8
39	Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
38	Novel patterns of complex structural variation revealed across thousands of cancer genome graphs		8
37	A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion. <i>Journal of Magnetic Resonance Imaging</i> , <b>2021</b> , 54, 462-471	5.6	8
36	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 6195	17.4	6
35	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 44	9.8	6
34	Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. <i>Gynecologic Oncology Reports</i> , <b>2019</b> , 28, 54-57	1.3	5
33	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 272-272	2.2	5
32	IQSeq: integrated isoform quantification analysis based on next-generation sequencing. <i>PLoS ONE</i> , <b>2012</b> , 7, e29175	3.7	5
31	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	5

30	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 1535-1546	5	4
29	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 584-590	4	4
28	Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples. <i>Thyroid</i> , <b>2021</b> , 31, 589-595	6.2	4
27	Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. <i>Cell Reports</i> , <b>2021</b> , 36, 109625	10.6	4
26	Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 80	7.3	3
25	G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 6662	17.4	3
24	Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 194-200	7.3	3
23	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 3372	17.4	3
22	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 786-793	6.2	3
21	Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. <i>European Urology Open Science</i> , <b>2020</b> , 22, 34-44	8.9	2
20	SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape		2
19	Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. <i>Translational Oncology</i> , <b>2021</b> , 14, 100944	4.9	2
18	BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	2
17	Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors. <i>Npj Genomic Medicine</i> , <b>2021</b> , 6, 66	6.2	2
16	Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. <i>J Pathol</i> 2013; 230: 453-456. <i>Journal of Pathology</i> , <b>2013</b> , 231, 271	9.4	1
15	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1435-1435	2.2	1
14	Role of Specialized Composition of SWI/SNF Complexes in Prostate Cancer Lineage Plasticity		1
13	MicroRNA-1205 Regulation of FRYL in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 647485	5.7	1

12	Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , <b>2021</b> , 26, e1971-e1981	5.7	1
11	Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.. <i>Journal of Pathology</i> , <b>2022</b> ,	9.4	1
10	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 6377	17.4	0
9	High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study. <i>Blood</i> , <b>2021</b> , 138, 138-138	2.2	0
8	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , <b>2021</b> , 4, 785	6.7	0
7	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , <b>2021</b> , 79, 736-746	10.2	0
6	Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8-8	2.2	
5	Combining Supervised and Unsupervised Methods to Support Early Diagnosis of Hepatocellular Carcinoma. <i>Lecture Notes in Computer Science</i> , <b>2003</b> , 239-243	0.9	
4	Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e17033 <sup>2</sup> -e17039	3.2	
3	The genomic landscape of metastatic clear cell renal cell carcinoma (ccRCC) after treatment with systemic therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 675-675	2.2	
2	Gene Fusions. <i>Molecular Pathology Library</i> , <b>2018</b> , 137-151		
1	Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 139-139	2.2	